BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25520723)

  • 21. Three distinct mechanisms underlying human γδ T cell-mediated cytotoxicity against malignant pleural mesothelioma.
    Umeyama Y; Taniguchi H; Gyotoku H; Senju H; Tomono H; Takemoto S; Yamaguchi H; Tagod MSO; Iwasaki M; Tanaka Y; Mukae H
    Front Immunol; 2023; 14():1058838. PubMed ID: 37006249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors.
    Biddle WC; Pancook J; Goldrosen M; Han T; Foon KA; Vaickus L
    Cancer Res; 1990 May; 50(10):2991-6. PubMed ID: 2334902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
    Csóka M; Strauss G; Debatin KM; Moldenhauer G
    Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ex vivo-expanded natural killer cells kill cancer cells more effectively than ex vivo-expanded γδ T cells or αβ T cells.
    Deng X; Terunuma H; Terunuma A; Takane T; Nieda M
    Int Immunopharmacol; 2014 Oct; 22(2):486-91. PubMed ID: 25131561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
    Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
    J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring kinetics reveals critical parameters of IgA-dependent granulocyte-mediated anti-tumor cell cytotoxicity.
    Zwick A; Bernhard M; Knoerck A; Linxweiler M; Schick B; Heinzelmann J; Smola S; Lohse S
    J Immunol Methods; 2019 Oct; 473():112644. PubMed ID: 31404549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes.
    de Palazzo IG; Gercel-Taylor C; Kitson J; Weiner LM
    Cancer Res; 1990 Nov; 50(22):7123-8. PubMed ID: 2146012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells.
    Niu C; Jin H; Li M; Xu J; Xu D; Hu J; He H; Li W; Cui J
    BMC Immunol; 2015 Oct; 16():61. PubMed ID: 26458364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma.
    Rossi C; Gravelle P; Decaup E; Bordenave J; Poupot M; Tosolini M; Franchini DM; Laurent C; Morin R; Lagarde JM; Ysebaert L; Ligat L; Jean C; Savina A; Klein C; Céspedes AM; Perez-Galan P; Fournié JJ; Bezombes C
    Oncoimmunology; 2019; 8(3):1554175. PubMed ID: 30723586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-signaling Chimeric Antigen Receptors Enhance Antigen-Directed Killing by γδ T Cells in Contrast to αβ T Cells.
    Fleischer LC; Becker SA; Ryan RE; Fedanov A; Doering CB; Spencer HT
    Mol Ther Oncolytics; 2020 Sep; 18():149-160. PubMed ID: 32671190
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy.
    Houot R; Kohrt HE; Marabelle A; Levy R
    Trends Immunol; 2011 Nov; 32(11):510-6. PubMed ID: 21907000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unusually efficient tumor cell lysis by human effectors of antibody-dependent cellular cytotoxicity mediated by monoclonal antibodies.
    Christiaansen JE; Sears DW
    Cancer Res; 1984 Sep; 44(9):3712-8. PubMed ID: 6744288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 51Cr release assay of antibody-dependent cell-mediated cytotoxicity (ADCC).
    Nelson DL; Kurman CC; Serbousek DE
    Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.27. PubMed ID: 18432838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
    Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW
    Br J Haematol; 2013 Oct; 163(2):182-93. PubMed ID: 23927424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells.
    Chung S; Lin YL; Reed C; Ng C; Cheng ZJ; Malavasi F; Yang J; Quarmby V; Song A
    J Immunol Methods; 2014 May; 407():63-75. PubMed ID: 24704820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
    Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
    Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation.
    Pfeiffer M; Stanojevic S; Feuchtinger T; Greil J; Handgretinger R; Barbin K; Jung G; Martin D; Niethammer D; Lang P
    Bone Marrow Transplant; 2005 Jul; 36(2):91-7. PubMed ID: 15908973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells.
    Deng X; Terunuma H; Nieda M; Xiao W; Nicol A
    Int Immunopharmacol; 2012 Dec; 14(4):593-605. PubMed ID: 23063974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.